retatrutide and heart rate rate: what the clinical data actually shows Inotropic effects of retatrutide in

Tirzepatide did not increase risks of adverse renal events, urinary tract infections, nephrolithiasis (kidney stones), acute kidney injury, or renal cancer compared to placebo, insulin, or other GLP-1 receptor agonists

It is a verification article, not a recommendation

There are four approved sites for the subcutaneous injection of insulin: Abdomen : You can do an injection anywhere outside a two-centimetre (or two-finger) radius around the navel

Some might be saying, isnt it already used for pediatric epilepsy

[DOI] [PMC free article] [PubMed] [Google Scholar] [233].Chen B, Yu X, Horvath-Diano C, Ortuo MJ, Tschp MH, Jastreboff AM, et al